Literature DB >> 12739736

Effect of small doses of dexamethasone on plasma leptin levels in normal and obese subjects: a dose-response study.

P Putignano1, A Brunani, A Dubini, M Bertolini, R Pasquali, F Cavagnini.   

Abstract

To further elucidate the role of glucocorticoids in the regulation of leptin secretion, we studied the effects of overnight small doses of dexamethasone on plasma leptin levels in normal weight controls and in obese patients and correlated the results with indexes of insulin sensitivity and body fat distribution. In 114 subjects (81 obese patients, 49 women and 32 men, BMI 37.4 +/- 0.77 kg/m2 and 33 normal-weight subjects, 17 women and 16 men, BMI 22.1 +/- 0.41 kg/m2) plasma F and leptin levels were measured at 08:00 h basally and after the administration of different doses of dexamethasone (a fixed dose of 1-mg and 0.0035, 0.007, 0.015-mg/kg bw, given po at 23:00 h the night before). Tests were performed one week apart with bw remaining stable over the study period. Basal leptin levels were significantly higher in obese than in normal subjects (31.9 +/- 2.41 vs 7.7 +/- 0.93 ng/ml, p<0.0001). In obese patients, leptin levels increased significantly by 1-mg (from 31.9 +/- 2.41 to 35.0 +/- 2.59 ng/ml, p<0.005) and the 0.015-mg/kg bw dose (from 31.5 +/- 2.34 to 33.7 +/- 2.44 ng/ml, p<0.05), while they were unaffected by each dose of dexamethasone in normal subjects. However, after splitting subjects by gender, mean leptin levels rose from 39.3 +/- 2.97 to 43.3 +/- 3.12 ng/ml after the 1-mg dose, p<0.005, from 39.1 +/- 2.87 to 43.6 +/- 2.91 ng/ml after the 0.015-mg/kg bw dose, p<0.005, from 39.3 +/- 2.90 to 42.2 +/- 2.90 ng/ml after the 0.007-mg/kg bw dose, p<0.05 and from 38.8 +/- 2.66 to 41.1 +/- 2.87 ng/ml after the 0.0035-mg/kg bw dose, p=0.055, only in obese women. Conversely, no leptin changes were seen in the other groups and no differences were observed in the leptin response between groups. After the 1-mg dose, in the whole group, the absolute leptin variation was weakly but significantly related to BMI values (r=0.231, p<0.02) while in all sessions the percent leptin changes over baseline were not significantly correlated with age, BMI, waist, WHR, insulin, HOMA index, a marker of insulin sensitivity, plasma dexamethasone concentrations and to the percent cortisol variation following dexamethasone. In conclusion, in obese women but not in obese men and in normal weight subjects, small overnight increases in plasma glucocorticoid concentrations induced gender-related plasma leptin elevations that were unrelated to body fat distribution and insulin sensitivity. A greater sensitivity of female adipose tissue to glucocorticoids probably underlies this sexually dimorphic pattern of leptin response. These findings provide an additional piece of information on the regulation of leptin secretion exerted by glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12739736     DOI: 10.1007/BF03345137

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  39 in total

1.  Plasma leptin levels do not change in healthy humans shortly after a hydrocortisone challenge.

Authors:  S Lautenbacher; J Hebebrand; W F Blum; H C Fehmann; J C Krieg
Journal:  Exp Clin Endocrinol Diabetes       Date:  1999       Impact factor: 2.949

2.  Relation of plasma leptin to lipoproteins in overweight children undergoing weight reduction.

Authors:  M Holub; K Zwiauer; C Winkler; B Dillinger-Paller; E Schuller; E Schober; S Stöckler-Ipsiroglou; W Patsch; W Strobl
Journal:  Int J Obes Relat Metab Disord       Date:  1999-01

3.  High leptin concentrations in serum of very obese children are further stimulated by dexamethasone.

Authors:  W Kiess; P Englaro; S Hanitsch; W Rascher; A Attanasio; W F Blum
Journal:  Horm Metab Res       Date:  1996-12       Impact factor: 2.936

4.  The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure.

Authors:  A Kennedy; T W Gettys; P Watson; P Wallace; E Ganaway; Q Pan; W T Garvey
Journal:  J Clin Endocrinol Metab       Date:  1997-04       Impact factor: 5.958

Review 5.  Glucocorticoids and depression.

Authors:  T Steckler; F Holsboer; J M Reul
Journal:  Baillieres Best Pract Res Clin Endocrinol Metab       Date:  1999-12

6.  Dexamethasone increases leptin expression in humans in vivo.

Authors:  S Papaspyrou-Rao; S H Schneider; R N Petersen; S K Fried
Journal:  J Clin Endocrinol Metab       Date:  1997-05       Impact factor: 5.958

7.  Dexamethasone, OB gene, and leptin in humans; effect of exogenous hyperinsulinemia.

Authors:  J W Kolaczynski; B J Goldstein; R V Considine
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

8.  Assessing depressive symptoms across cultures: Italian validation of the CES-D self-rating scale.

Authors:  G A Fava
Journal:  J Clin Psychol       Date:  1983-03

9.  Synergistic effects of feeding and dexamethasone on serum leptin levels.

Authors:  B Laferrère; S K Fried; K Hough; S A Campbell; J Thornton; F X Pi-Sunyer
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

10.  The acute effect of dexamethasone on plasma leptin concentrations and the relationships between fasting leptin, the IGF-I/IGFBP system, dehydroepiandrosterone, androstenedione and testosterone in an elderly population.

Authors:  J A Janssen; N A Huizenga; R P Stolk; D E Grobbee; H A Pols; F H de Jong; A M Attanasio; W F Blum; S W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  1998-05       Impact factor: 3.478

View more
  2 in total

Review 1.  Leptin and cardiovascular disease: response to therapeutic interventions.

Authors:  Kwang Kon Koh; Sang Min Park; Michael J Quon
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

2.  Effects of short-term corticoid ingestion on food intake and adipokines in healthy recreationally trained men.

Authors:  N Rieth; L Jollin; B Le Panse; A-M Lecoq; A Arlettaz; J De Ceaurriz; K Collomp
Journal:  Eur J Appl Physiol       Date:  2008-11-05       Impact factor: 3.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.